๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hepatitis C: Current options for nonresponders to peginterferon and ribavirin

โœ Scribed by Emmanuel Thomas; Michael W. Fried

Book ID
107538355
Publisher
Springer
Year
2008
Tongue
English
Weight
259 KB
Volume
10
Category
Article
ISSN
1522-8037

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Rapid virological response to peginterfe
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight-based ribavirin exposure
โœ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Wan-Long Chuang ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 64 KB ๐Ÿ‘ 1 views

contraindicate the use of drugs such as hydroxymethyl-glutaryl-coenzyme A inhibitors (statins). Statins, as the most popular cholesterollowering agents, are widely used in the MS and display in vitro anti-HCV properties. 6 However, results from an in vivo pilot study with atorvastatin have been disa

Risk factors for infection during treatm
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
โœ Robert Roomer; Bettina E. Hansen; Harry L. A. Janssen; Robert J. de Knegt ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 136 KB ๐Ÿ‘ 2 views

Neutropenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C virus (HCV) infection is a common cause of dose reductions of peginterferon alfa. These reductions are performed to prevent bacterial and fungal infections, which are common during HCV treatment and can be att